^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    delpazolid (LCB01-0371)

    i
    Other names: LCB01-0371, LCB-01371, RMX 2001
    Company:
    HaiHe Biopharma, LigaChem Biosci
    Drug class:
    Protein synthesis inhibitor
    Related drugs:
    4ms
    Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, LigaChem Biosciences, Inc. | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Nov 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    delpazolid (LCB01-0371)
    over1year
    Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex (clinicaltrials.gov)
    P2, N=20, Recruiting, LigaChem Biosciences, Inc. | Active, not recruiting --> Recruiting
    Enrollment open
    |
    delpazolid (LCB01-0371)